Fewer than a tenth of people that would benefit from GLP-1 drugs such as Wegovy have access to them, states the World Health Organization as it publishes its inaugural recommendations on the medications.
With over a billion individuals worldwide now obese, it is advocating for increased and just access to GLP-1 medication.
According to forecasts, over two billion will be obese by 2030 without intervention.
"Our latest guidance recognises that excess weight is a lifelong illness that can be managed with comprehensive and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are major hurdles to broad availability to the injections that can assist patients in reducing considerable body mass, says the organization.
GLP-1 Therapy Supply Crisis
Despite the present most favorable case, the production of these medications would only suffice for around 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline encourages countries and companies to expand availability, by measures such as licensing agreements.
A patent on semaglutide – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Function
The injections imitate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so people reduce food intake.
Individuals usually see weight reduction within a few weeks of commencing the regular doses.
Evidence points to users may regain a significant portion a year later of stopping the medication, because their typical hunger return.
Being above a healthy weight elevates your chance for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the health agency.
